CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts

Table 1 Antitumor effects of i.p. CpG-ODN1826 (20 µg/mouse, qdx5d/wx4w) against early- and late-stage DMPM orthotopic xenografts

Model	Drug	Treatment start (day)	Tumor take^a	Tumor weight (mg)		TWI %^b	P ^c
Model	Drug	Treatment start (day)	Tumor take^a	Median	Mean ± SD	TWI %^b	P ^c
MesoII	Saline	4	6/6	1360	1460 ± 776
	CpG-ODN1826		0/6	–	–
STO	Saline	4	6/6	625	695 ± 206
	CpG-ODN1826		2/6	0	43 ± 60	94	0.00005
	Saline	11	10/10	996	1120 ± 550
	CpG-ODN1826		10/10	340	381 ± 99	66	0.0009

MesoII and STO cells (2.5 × 10⁷ and 10⁷/mouse, respectively) were inoculated i.p. in female SCID mice on day 0. Animals were sacrificed at ascites onset (MesoII) or the day after the last CpG-ODN1826 administration (STO); i.p. tumor masses were removed and weighed
^aNumber of mice with i.p. macroscopic tumors out of number of DMPM cell-injected mice
^bTumor weight inhibition percentage in treated over control mice
^cBy Student’s t test over saline-treated control mice

ISSN: 1479-5876